2024-01-26 10:04:59 ET
Summary
- Ginkgo Bioworks focuses on its Foundry and Code Base assets to offer R&D services and drive down costs for clients.
- The company secures a significant deal with Pfizer in the drug discovery category, demonstrating the scalability of its sales team.
- Nevertheless, the company's recent financial developments and revenue growth are not enthusiastic.
Ginkgo Bioworks ( DNA ) has been a focal point in previous discussions , notably for its two primary assets: the Foundry and the Code Base. The Foundry operates as an automated laboratory, enabling the transformation of R&D investments from fixed to variable costs, offered as a service. The Code Base, on the other hand, serves as a repository of experimental data, aiding in enhancing the success rates of programs while concurrently driving down costs for clients....
Read the full article on Seeking Alpha
For further details see:
Ginkgo Bioworks At The Intersection Of Cutting-Edge Technology And Financial Disappointment